Literature DB >> 26747892

Tracking Down Response and Resistance to TRK Inhibitors.

Ross A Okimoto1, Trever G Bivona2.   

Abstract

Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer subtypes. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26747892      PMCID： PMC4709026          DOI： 10.1158/2159-8290.CD-15-1352

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Lung cancer in the era of precision medicine.

Authors:  Katerina Politi; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 4.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

5.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

6.  The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Authors:  Elena Ardini; Roberta Bosotti; Andrea Lombardi Borgia; Cristina De Ponti; Alessio Somaschini; Rosaria Cammarota; Nadia Amboldi; Laura Raddrizzani; Andrea Milani; Paola Magnaghi; Dario Ballinari; Daniele Casero; Fabio Gasparri; Patrizia Banfi; Nilla Avanzi; Maria B Saccardo; Rachele Alzani; Tiziano Bandiera; Eduard Felder; Daniele Donati; Enrico Pesenti; Andrea Sartore-Bianchi; Marcello Gambacorta; Marco A Pierotti; Salvatore Siena; Silvio Veronese; Arturo Galvani; Antonella Isacchi
Journal:  Mol Oncol       Date:  2014-06-12       Impact factor: 6.603

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Authors:  Robert C Doebele; Lara E Davis; Aria Vaishnavi; Anh T Le; Adriana Estrada-Bernal; Stephen Keysar; Antonio Jimeno; Marileila Varella-Garcia; Dara L Aisner; Yali Li; Philip J Stephens; Deborah Morosini; Brian B Tuch; Michele Fernandes; Nisha Nanda; Jennifer A Low
Journal:  Cancer Discov       Date:  2015-07-27       Impact factor: 39.397

9.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Authors:  Mariangela Russo; Sandra Misale; Ge Wei; Giulia Siravegna; Giovanni Crisafulli; Luca Lazzari; Giorgio Corti; Giuseppe Rospo; Luca Novara; Benedetta Mussolin; Alice Bartolini; Nicholas Cam; Roopal Patel; Shunqi Yan; Robert Shoemaker; Robert Wild; Federica Di Nicolantonio; Andrea Sartore Bianchi; Gang Li; Salvatore Siena; Alberto Bardelli
Journal:  Cancer Discov       Date:  2015-11-06       Impact factor: 39.397

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440
  10 in total
  5 in total

1.  Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.

Authors:  Aria Vaishnavi; Michael T Scherzer; Conan G Kinsey; Gennie L Parkman; Amanda Truong; Phaedra Ghazi; Sophia Schuman; Benjamin Battistone; Ignacio Garrido-Laguna; Martin McMahon
Journal:  Cell Rep       Date:  2020-08-04       Impact factor: 9.423

2.  Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Authors:  Christopher Alvarez-Breckenridge; Julie J Miller; Tracy T Batchelor; A John Iafrate; Priscilla K Brastianos; Naema Nayyar; Corey M Gill; Andrew Kaneb; Megan D'Andrea; Long P Le; Jesse Lee; Ju Cheng; Zongli Zheng; William E Butler; Pratik Multani; Edna Chow Maneval; Sun Ha Paek; Brian D Toyota; Dora Dias-Santagata; Sandro Santagata; Javier Romero; Alice T Shaw; Anna F Farago; Stephen Yip; Daniel P Cahill
Journal:  NPJ Precis Oncol       Date:  2017-03-20

3.  Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.

Authors:  Jessica M Konen; B Leticia Rodriguez; Jared J Fradette; Laura Gibson; Denali Davis; Rosalba Minelli; Michael D Peoples; Jeffrey Kovacs; Alessandro Carugo; Christopher Bristow; Timothy Heffernan; Don L Gibbons
Journal:  Cancers (Basel)       Date:  2019-04-02       Impact factor: 6.639

4.  Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.

Authors:  P Garrido; R Hladun; E de Álava; R Álvarez; F Bautista; F López-Ríos; R Colomer; F Rojo
Journal:  Clin Transl Oncol       Date:  2021-02-23       Impact factor: 3.405

5.  Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.

Authors:  Jeongwan Kang; Jin Woo Park; Jae-Kyung Won; Jeong Mo Bae; Jaemoon Koh; Jeemin Yim; Hongseok Yun; Seung-Ki Kim; Jung Yoon Choi; Hyoung Jin Kang; Woo Sun Kim; Joo Heon Shin; Sung-Hye Park
Journal:  Diagn Pathol       Date:  2020-09-21       Impact factor: 2.644
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.